Grail (GRAL) shares were cut in half on Feb. 20 after the biotech firm said its highly anticipated NHS-Galleri clinical trial failed to meet its primary endpoint. As retail and institutional investors bailed on GRAL today, its 14-day relative strength index (RSI) crashed to 24, indicating a technical rebound was likely in the near term. More News from Barchart Still, investors are recommended against buying the dip in Grail stock, even though it looks like a bargain at about $49. www.barchart.com Sho ...

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-grail-inc-investigation-gral.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 8 ...

This isn't a good day for investors in Grail (NASDAQ: GRAL). The stock declined more than 50% by 1:30 p.m. today. The move comes on the day of its fourth-quarter earnings results, but more importantly, the release of its top-line results from a major trial of its Galleri multi-cancer early detection (MCED) test in England's National Health Service (NHS). As you have already surmised, the trial did not go as planned. What went wrong The first bullet point of the results release is what investors are focusi ...

Why Grail Stock Has Plunged 50% Despite Earnings Beat - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Why Grail Stock Has Plunged 50% Despite Earnings BeatBy [Mackenzie Tatananni]and [Callum Keown]ShareResize---ReprintsIn this article[GRAL] ...

Core Insights - Grail Inc. is a biotechnology company focused on early cancer detection, particularly through its multi-cancer screening test, Galleri, which aims to identify cancer at early stages [1] - The company operates in a competitive landscape with other biotech firms also striving for advancements in cancer diagnostics [1] Stock Performance - On February 20, 2026, Canaccord Genuity set a new price target of $80 for Grail, indicating a potential downside of approximately -21.21% from the stock's trading price of $101.53 at that time [2] - Grail's stock has experienced a dramatic plunge of 50% following disappointing results from a U.K. trial of Galleri, which did not achieve a statistically significant reduction in stage 3 and 4 cancer cases [3] - Currently, Grail's stock is priced at $101.53, reflecting a decrease of 0.75, or -0.73% [4] - Over the past year, Grail's stock has shown significant volatility, reaching a high of $118.84 and a low of $20.44 [4] Market Capitalization and Trading Volume - Grail's market capitalization is approximately $3.96 billion, with a trading volume of 1,545,372 shares on the NASDAQ exchange [5] - Recent developments and the price target adjustment by Canaccord Genuity highlight the challenges Grail faces in regaining investor confidence and stabilizing its stock performance [5]

Biotech stock Grail Inc (NASDAQ:GRAL) is taking a nosedive today, brushing off better-than-expected fourth-quarter results after the company's three-year cancer screening trial failed to meet its main goal. Last seen down 47.7% at $53.11, the equity is headed for its largest single-day percentage drop on record as it hits its lowest levels since September. Grail is a spinoff of Illumina (ILMN), and has been publicly traded since June 2024. Year over year, shares are still holding on to an 11% lead, though t ...

Core Viewpoint - Grail's shares dropped nearly 50% after its three-year cancer screening trial failed to meet its primary goal, significantly impacting the company [1] Company Summary - Grail's three-year cancer screening trial aimed to demonstrate a reduction in late-stage cancer diagnoses and improve early detection within the National Health Service (NHS) [1] - The trial involved over 142,000 participants aged 50 to 77 years, but the main goal of achieving a statistically significant reduction was not met, although a favorable trend was noted over time [1] - Grail had previously filed for U.S. regulatory approval of its Galleri test based on data from a smaller U.S. trial and the first-year data from the larger trial [1] Industry Summary - The Galleri multi-cancer early detection test is recommended for adults aged 50 and older with an elevated risk for cancer [1] - The approval of Galleri by the FDA does not appear to be at material risk, but the consideration of NHS data by the Centers for Medicare and Medicaid Services (CMS) for coverage policy remains uncertain [1] - Recent legislation allows for insurance coverage of multi-cancer early detection tests under Medicare plans for older adults starting in 2028, depending on age [1]

Core Insights - The biotech company reported that its multi-cancer screening test, Galleri, did not achieve a statistically significant reduction in stage 3 and 4 cancer during a trial conducted in the U.K. [1] Company Summary - The company is focused on developing innovative cancer screening solutions [1] - Galleri is positioned as a multi-cancer screening test aimed at early detection [1] Industry Summary - The trial results highlight challenges in the effectiveness of current cancer screening technologies [1] - The findings may impact the perception and adoption of multi-cancer screening tests in the healthcare market [1]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims for Grail, Inc. investors regarding losses that may be recoverable under federal securities laws following the company's failure to meet clinical trial endpoints [1][1]. Group 1: Investigation Details - The investigation focuses on Grail's executive officers and their compliance with federal securities laws [1]. - Grail disclosed on February 19, 2026, that its NHS-Galleri trial did not achieve its primary clinical endpoint, leading to a significant decline of approximately 48% in share price during after-hours trading [1][1]. Group 2: Investor Information - Investors who purchased Grail securities and suffered losses are encouraged to join the investigation without any cost or obligation [1]. - Contact information for inquiries includes Jim Baker at (619) 814-4471 or via email [1]. Group 3: Johnson Fistel Overview - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, with a history of recovering approximately $90.725 million for clients [1][1]. - The firm has been ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, marking its eighth recognition as a top plaintiffs' securities law firm in the U.S. [1].

US stock futures slid on Friday as investors digested economic data that showed US economic growth cooling in the fourth quarter, while the Fed's favored inflation gauge heated up to end last year. Wall Street also kept an eye out for US-Iran tensions, private credit jitters, and a potential Supreme Court tariff decision. Contracts on the S&P 500 (ES=F) moved down roughly 0.3%, while Dow Jones Industrial Average futures (YM=F) fell 0.2%, coming off the end of a three-day winning streak on Thursday. Nasdaq ...